Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Hecht, Y. Bang, S. Qin, H. Chung, Jianming Xu, Joon-Oh Park, K. Jeziorski, Y. Shparyk, P. Hoff, A. Sobrero, P. Salman, Jin Li, S. Protsenko, Z. Wainberg, M. Buyse, K. Afenjar, V. Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, S. Khan-Wasti, S. Santillana, M. Press, D. Slamon (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 5
Y. Yamada, K. Higuchi, K. Nishikawa, M. Gotoh, N. Fuse, N. Sugimoto, T. Nishina, K. Amagai, K. Chin, Y. Niwa, A. Tsuji, H. Imamura, M. Tsuda, H. Yasui, H. Fujii, K. Yamaguchi, H. Yasui, S. Hironaka, K. Shimada, H. Miwa, C. Hamada, I. Hyodo (2015)
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 26 1
L. Shen, Jin Li, Jianming Xu, H. Pan, G. Dai, S. Qin, Li-wei Wang, Jinwan Wang, Zhenzhou Yang, Y. Shu, R. Xu, Lei Chen, Yunpeng Liu, Shiying Yu, L. Bu, Y. Piao (2014)
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)Gastric Cancer, 18
Japanese Association (2016)
Japanese gastric cancer treatment guidelines 2014 (ver. 4)Gastric Cancer, 20
K. Shitara, S. Kadowaki, T. Nishina, D. Sakai, R. Yoshikawa, Y. Piao, Akihiro Ozeki, Koichi Inoue, Ismael Gritli, K. Muro (2017)
Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancerGastric Cancer, 21
C. Fuchs, J. Tomasek, Cho Yong, Filip Dumitru, R. Passalacqua, C. Goswami, H. Safran, L. Santos, G. Aprile, D. Ferry, B. Melichar, M. Tehfé, E. Topuzov, J. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A. Liepa, L. Gao, J. Schwartz, J. Tabernero (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 383
K. Muro, S. Oh, Y. Shimada, Keun-Wook Lee, C. Yen, Y. Chao, J. Cho, R. Cheng, R. Carlesi, K. Chandrawansa, M. Orlando, A. Ohtsu (2016)
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancerJournal of Gastroenterology and Hepatology, 31
J. Tabernero, A. Ohtsu, K. Muro, E. Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, J. Ajani, J. Tomasek, H. Safran, K. Chandrawansa, Y. Hsu, M. Heathman, Azhar Khan, L. Ni, A. Melemed, L. Gao, D. Ferry, C. Fuchs (2017)
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction CancerMolecular Cancer Therapeutics, 16
G. Bocci, A. Paolo, R. Danesi (2013)
The pharmacological bases of the antiangiogenic activity of paclitaxelAngiogenesis, 16
(2013)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.JAMA, 310 20
T. Sano (2017)
Gastric cancer: Asia and the worldGastric Cancer, 20
R. Cook, B. Dickens, M. Fathalla (2003)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.The Journal of the American College of Dentists, 81 3
J. Ajani, T. D’amico, K. Almhanna, D. Bentrem, J. Chao, P. Das, C. Denlinger, P. Fanta, F. Farjah, C. Fuchs, H. Gerdes, M. Gibson, R. Glasgow, J. Hayman, S. Hochwald, W. Hofstetter, D. Ilson, D. Jaroszewski, K. Johung, R. Keswani, L. Kleinberg, W. Korn, S. Leong, Catherine Linn, A. Lockhart, Quan Ly, M. Mulcahy, M. Orringer, K. Perry, G. Poultsides, W. Scott, V. Strong, M. Washington, B. Weksler, C. Willett, C. Wright, Debra Zelman, Nicole Mcmillian, Hema Sundar (2016)
Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in OncologyJournal of The National Comprehensive Cancer Network, 14
C. Fontanella, E. Ongaro, S. Bolzonello, M. Guardascione, G. Fasola, G. Aprile (2014)
Clinical advances in the development of novel VEGFR2 inhibitors.Annals of translational medicine, 2 12
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
J. Bennouna, J. Sastre, D. Arnold, P. Österlund, R. Greil, E. Cutsem, R. Moos, J. Viéitez, O. Bouché, C. Borg, C. Steffens, V. Alonso-Orduña, C. Schlichting, I. Reyes-Rivera, B. Bendahmane, T. André, S. Kubicka (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.The Lancet. Oncology, 14 1
C. Fuchs, K. Shitara, M. Bartolomeo, S. Lonardi, S. Al-Batran, E. Cutsem, D. Ilson, M. Alsina, I. Chau, J. Lacy, M. Ducreux, G. Mendez, Alejandro Alavez, D. Takahari, W. Mansoor, P. Enzinger, V. Gorbounova, Z. Wainberg, S. Hegewisch‐Becker, D. Ferry, Ji Lin, R. Carlesi, M. Das, M. Shah (2019)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.The Lancet. Oncology, 20 3
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
H. Wilke, K. Muro, E. Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, Tae-You Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J. Schwartz, A. Ohtsu (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.The Lancet. Oncology, 15 11
A. Ohtsu, M. Shah, E. Cutsem, S. Rha, A. Sawaki, Sook Park, Ho Lim, Y. Yamada, Jian Wu, B. Langer, M. Starnawski, Yoon-Koo Kang (2011)
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 30
Ajani (2016)
Gastric cancer, version 3.2016, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, 14
H. Yoon, J. Bendell, F. Braiteh, I. Firdaus, P. Philip, A. Cohn, N. Lewis, D. Anderson, E. Arrowsmith, J. Schwartz, L. Gao, Y. Hsu, Y. Xu, D. Ferry, S. Alberts, Z. Wainberg (2019)
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.Annals of oncology : official journal of the European Society for Medical Oncology, 30 12
Key PointsQuestionDoes the addition of ramucirumab to S-1 and oxaliplatin improve progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma in the first-line setting? FindingsIn this phase 2 randomized clinical trial of 189 East Asian patients with metastatic gastric or gastroesophageal junction adenocarcinoma, median progression-free survival was not prolonged in the ramucirumab plus S-1 and oxaliplatin arm compared with the placebo plus S-1 and oxaliplatin arm (6.34 vs 6.74 months). MeaningAddition of ramucirumab to first-line S-1 and oxaliplatin treatment did not improve progression-free survival, suggesting that the efficacy of ramucirumab in the second-line setting may not be applicable to the first-line setting when combined with fluoropyrimidine and platinum chemotherapy.
JAMA Network Open – American Medical Association
Published: Aug 2, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.